The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

15 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization.EBI
Bristol Myers Squibb Research and Early Development
Cancer Immunotherapy through the Inhibition of Diacylglycerol Kinases Alpha and Zeta.EBI
Therachem Research Medilab
Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease.EBI
Glaxosmithkline R&D
Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.EBI
Astrazeneca
FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORSBDB
Aurigene Oncology
PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORSBDB
Actelion Pharmaceuticals
Indazole compound or salt thereofBDB
Taiho Pharmaceutical Co.
Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseasesBDB
Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung
Leucine-rich repeat kinase 2 (LRRK2) inhibitorsBDB
H. Lundbeck
BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOFBDB
Beigene Switzerland
COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERSBDB
Kineta
Alkyne-containing antiviral agentsBDB
Enanta Pharmaceuticals
SUBSTITUTED S-ALANINATE DERIVATIVESBDB
Bayer Aktiengesellschaft
Inhibiting mutant IDH-1BDB
Forma Therapeutics
Ethynyl derivativesBDB
Hoffmann-La Roche